General Hospital Medicine   

Has recent data showing mortality benefit in resource-limited settings swayed your practice?

How do you consider recent data supporting shorter antibiotic courses? What factors push you toward a longer course?

Do symptom resolution or time-based strategies drive your decision?

Klementova et al., PMID 40795115

Considering the recent article in CHEST that describes the increasing incidence of fungal pneumonia Azar. Chest 2024

Leem et al., PMID 37713527Smith et al., PMID 40961256

If yes, which combination(s)?

Are there situations in which you still feel comfortable giving IV iron? If not, do you consider PO iron?

McCreary et al., PMID 37310038

Hatzl et al., PMID 40971881

Do you still find urinalysis helpful in this situation, or do you rely on more specific culture data, imaging studies, etc.?

Do you involve additional specialists, such as ENT, to further evaluate? Is there a particular algorithm followed by your institution, or is it just d...

Rogers & Rice, PMID 38018162

If placed for this indication, how do you decide when to remove?

In other words, are there benefits to identifying URI pathogens that do not necessarily have targeted therapies (e.g., rhinovirus, non-COVID-19 Corona...

Tabaja et al., PMID 38635420

Are there situations in which you would continue the possible offending agent with close monitoring?

For example, do you find trending WBC, procalcitonin, CRP, etc., more or less helpful?

What situations prompt you to prescribe dexamethasone to complete a 10-day course at discharge?

Would you be comfortable with the use of DOACs?

Do you extend the course of fidaxomicin past initial 10 days to at least 3-7 days after completion of antibiotics?